Mecasermin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Mecasermin
Clinical data
Trade names Increlex
Synonyms FK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1
AHFS/Drugs.com Monograph
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Subcutaneous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C331H512N94O101S7
Molar mass 7648.67 g/mol
 ☒N☑Y (what is this?)  (verify)

Mecasermin (INN) (brand name Increlex), also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is recombinant form of human insulin-like growth factor 1 (IGF-I) which is used for the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).[1][2]

A related drug is mecasermin rinfabate (trade name Iplex), which is a combination of rhIGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 serves to prolong the action of IGF-1 in the human body.

References[edit]

  1. ^ Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management. 5 (3): 553–9. doi:10.2147/tcrm.s6178. PMC 2724186. PMID 19707272.
  2. ^ "Increlex". Drugs.com. Retrieved 10 January 2010.